Effects of roxithromycin, erythromycin and troleandomycin on their N-demethylation by rat and human cytochrome P450 enzymes

Xenobiotica

Volumn 26, Issue 11, 1996, Pages 1143-1153

  Yamazaki, H ^a   Hiroki, S ^b   Urano, T ^c   Inoue, K ^a   Shimada, T ^a  

^a OSAKA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^b Roussel Morishita Co Ltd   (Japan)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA CYANOPREGNENOLONE; BENZPHETAMINE; CARBAMAZEPINE; CIMETIDINE; CYTOCHROME P450; DEXAMETHASONE; DIAZEPAM; ERYTHROMYCIN; KETOCONAZOLE; METHYLPREDNISOLONE; METYRAPONE; NARINGENIN; NIFEDIPINE; PHENOBARBITAL; PHENYTOIN; PREDNISOLONE; ROXITHROMYCIN; TROLEANDOMYCIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG METABOLISM; DRUG OXIDATION; ENZYME INDUCTION; HUMAN; HUMAN TISSUE; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER MICROSOME; MALE; NONHUMAN; RAT;

ANIMALIA;

EID: 0029974084     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.3109/00498259609050259     Document Type: Article

References (43)

1. BAILEY, D. G., 1995, Food-drug interactions: emphasis on grapefruit juice effects. Canadian Journal of Clinical Pharmacology, 2, 10-14.
2. BAILEY, D. G., ARNOLD, J. M. O., BEND, J. R., THAN, L. T., and SPENCE, J. D., 1995, Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. British Journal of Clinical Pharmacology, 40, 135-140.
3. BIRKETT, D. J., ROBSON, R. A., GRGURINOVICH, N. and TONKIN, A., 1990, Single oral dose pharmacokinetics of erythromycin and roxithromycin and the effects of chronic dosing. Therapeutic Drug Monitoring, 12, 65-71.
4. BOSSCHE, H. V., KOYMANS, L., and MOEREELS, H., 1995, P450 inhibitors of use in medical treatment: focus on mechanisms of action. Pharmacology and Therapeutics, 67, 79-100.
5. COUTTS, R. T., SU, P. and BAKER, G. B., 1994, Involvement of CYP2D6, CYP3A4, and other cytochrome P-450 isozymes in N-dealkylation reactions. Journal of Pharmacological and Toxicological Methods, 31, 177-186.
6. DELAFORGE, M., SARTORI, E., and MANSUY, D., 1988, In vivo and in vitro effects of a new macrolide antibiotic roxithromycin on rat liver cytochrome P-450: comparison with troleandomycin and erythromycin. Chemico-Biological Interactions, 68, 179-188.
7. GILLAM, E., BABA, T., KIM, B. R., OHMORI, S., and GUENGERICH, F. P., 1993, Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Archives of Biochemistry and Biophysics, 305, 123-131.
8. GILLUM, J. G., ISRAEL, D. S., and POLK, R. E., 1993, Pharmacokinetic drug interactions with antimicrobial agents. Clinical Pharmacokinetics, 25, 450-482.
9. GONZALEZ, F. J., 1990, Molecular genetics of the P-450 superfamily. Pharmacology and Therapeutics, 45, 1-38.
10. GUENGERICH, F. P., 1994, Analysis and characterization of enzymes. In Principles and Methods of Toxicology, edited by A. W. Hayes (New York: Raven), pp. 1259-1313.
11. GUENGERICH, F. P., MARTIN, M. V., BEAUNE, P. H., KREMERS, P., WOLFF, T., and WAXMAN, D. J., 1986, Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry, 261, 5051-5060.
12. GUENGERICH, F. P. and SHIMADA, T., 1991, Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chemical Research in Toxicology, 4, 391-407.
13. GUENGERICH, F. P., WANG, P., and DAVIDSON, N. K., 1982, Estimation of isozymes of microsomal cytochrome P-450 in rats, rabbits, and humans using immunochemical staining coupled with sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Biochemistry, 21, 1698-1706.
14. HA, H. R., CHEN, J., LEUENBERGER, P. M., FREIBURGHAUS, A. U., and FOLLATH, F., 1995, In vitro inhibition of midazolam and quinidine metabolism by flavonoids. European Journal of Clinical Pharmacology, 48, 367-371.
15. HONIG, P. K., WORTHAM, D. C., ZAMANI, K., CONNER, D. P., MULLIN, J. C., and CANTILENA, L. R., 1993, Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. Journal of the American Medical Association, 269, 1513-1518.
16. 5 in reconstituted monooxygenase systems containing various forms of hepatic microsomal cytochrome P-450. Journal of Biochemistry, 89, 351-362.
17. IMAOKA, S., FUJITA, S., and FUNAE, Y., 1991, Age-dependent expression of cytochrome P-450s in rat liver. Biochimica et Biophysica Acta, 1097, 187-192.
18. IMAOKA, S., TERANO, Y., and FUNAE, Y., 1988, Constitutive testosterone 6β-hydroxylase in rat liver. Journal of Biochemistry, 104, 481-487.
19. KAMINSKY, L. S., FASCO, M. J., and GUENGERICH, F. P., 1981, Production and application of antibodies to rat liver cytochrome P-450. Methods in Enzymology, 74, 262-272.
20. KETTERER, T. A., FLOCKHART, D. A., POST, R. M., DENICOFF, K., PAZZAGLLA, P. J., MARANGELL, L. B., GEORGE, M. S., and CALLAHAN, A. M., 1995, The emerging role of cytochrome P450 3A in psychopharmacology. Journal of Clinical Psychopharmacology, 15, 387-398.
21. KIVISTÖ, K. T., KROEMER, H. K., and EICHELBAUM, M., 1995, The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. British Journal of Clinical Pharmacology, 40, 523-530.
22. KOCAREK, T. A., SCHUETZ, E. G., STROM, S. C., FISHER, R. A., and GUZELIAN, P. S., 1995, Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug Metabolism and Disposition, 23, 415-421.
23. LARREY, D., FUNCK-BRENTANO, C., BREIL, P., VITAUX, J., THEODORE, C., BABANY, G., and PESSAYRE, D., 1983, Effects of erythromycin on hepatic drug metabolising enzymes in humans. Biochemical Pharmacology, 32, 1063-1068.
24. LEVY, R. H., 1995, Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia, 36, S8-13.
25. LI, A. P., RASMUSSEN, A., XU, L., and KAMINSKI, D. L., 1995, Rifampicin induction of lidocaine metabolism in cultured human hepatocytes. Journal of Pharmacology and Experimental Therapeutics, 274, 673-677.
26. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L., and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
27. MÄENPÄÄ, J., PELKONEN, O., CRESTEIL, T., and RANE, A., 1993, The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. Journal of Steroid Biochemistry and Molecular Biology, 44, 61-67.
28. NASH, T., 1953, The colorimetric estimation of formaldehyde by means of the Hantzsch reaction. Biochemical Journal, 55, 416-421.
29. OMURA, T., and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. Journal of Biological Chemistry, 239, 2370-2378.
30. PERITI, P., MAZZEI, T., MINI, E., and NOVELLI, A., 1992, Pharmacokinetic drug interactions of macrolides. Clinical Pharmacokinetics, 23, 106-131.
31. ROBINSON, R. C., NAGATA, K., GELBOIN, H. V., RIFKIND, J., GONZALEZ, F. J., and FRIEDMAN, F. K., 1990, Developmental regulation of hepatic testosterone hydroxylases: simultaneous activation and repression of constitutively expressed cytochromes P450 in senescent rats. Archives of Biochemistry and Biophysics, 277, 42-46.
32. SHIMADA, T., IWASAKI, M., MARTIN, M. V., and GUENGERICH, F. P., 1989, Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA1535/pSK1002. Cancer Research, 49, 3218-3228.
33. SHIMADA, T. and NAKAMURA, S., 1987, Cytochrome P-450-mediated activation of procarcinogens and promutagens to DNA-damaging products by measuring expression of umu gene in Salmonella typhimurium TA1535/pSK1002. Biochemical Pharmacology, 36, 1979-1987.
34. 1 by constitutive forms of cytochrome P-450 in rat liver microsomes. Toxicology and Applied Pharmacology, 91, 13-21.
35. SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y., and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals : studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414-423.
36. TANIGUCHI, H., IMAI, Y., INYANAGI, T., and SATO, R., 1979, Interaction between NADPH-cytochrome P-450 reductase and cytochrome P-450 in the membrane of phosphatidylcholine vesicles. Biochimica et Biophysica Acta, 550, 341-356.
37. UPTON, R. A., 1991, Pharmacokinetic interactions between theophylline and other medication (Part I). Clinical Pharmacokinetics, 20, 66-80.
38. WATKINS, P. B., TURGEON, D. K., SAENGER, P., LOWN, K. S., KOLARS, J. C., HAMILTON, T., FISHMAN, K., GUZELIAN, P. S., and VOORHEES, J. J., 1992, Comparison of urinary 6-β-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clinical Pharmacology and Therapeutics, 52, 265-273.
39. WRIGHTON, S. A., RING, B. J., and VANDENBRANDEN, M., 1995, The use of in vitro metabolism Techniques in the planning and interpretation of drug safety studies. Toxicology and Pathology, 23, 199-208.
40. WRIGHTON, S. A., and STEVENS, J. C., 1992, The human hepatic cytochromes P450 involved in drug metabolism. Critical Reviews in Toxicology, 22, 1-21.
41. YAMAZAKI, H., GUO, Z., PERSMARK, M., MIMURA, M., INOUE, K., GUENGERICH, F. P., and SHIMADA, T., 1994, Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Molecular Pharmacology, 46, 568-577.
42. 5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. Archives of Biochemistry and Biophysics, 325, 174-182.
43. YASUKOCHI, Y. and MASTERS, B., 1976, Some properties of a detergent-solubilized NADPH-cytochrome c (cytochrome P-450) reductase purified by biospecific affinity chromatography. Journal of Biological Chemistry, 251, 5337-5344.